Tryptamine Therapeutics (ASX:TYP) hits major milestone in psychedelic drug development
Tryptamine Therapeutics has reached a pivotal milestone with the successful safety evaluation of its IV-infused psilocin formulation, TRP-8803, setting the stage for broader clinical trials.